Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†

David E. Kleiner, Elizabeth M. Brunt, Mark L. Van Natta et al. · Hepatology · 2005 · 10.7K citations

Medicine, Pathology, Gastroenterology +16

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

Eduardo Vilar‐Gómez, Yadina Martínez-Pérez, Luis Calzadilla Bertot et al. · Gastroenterology · 2015 · 2.4K citations · Full text

Medicine, Internal Medicine, Nutritional Sciences +11

Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study

Christopher D. Williams, Joel Z. Stengel, Michael Asike et al. · Gastroenterology · 2010 · 2.2K citations · Full text

Medicine, Internal Medicine, Hepatology +14

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice

Jing Xu, David J. Lloyd, Clarence Hale et al. · Diabetes · 2008 · 1.1K citations · Full text

Life Sciences, Biochemistry, Endocrinology +17